LeMaitre Vascular (NASDAQ:LMAT) Releases Q4 2024 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its fourth quarter 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 0.470-0.510 for the period, compared to the consensus earnings per share estimate of 0.460. The company issued revenue guidance of $54.9 million-$56.9 million, compared to the consensus revenue estimate of $55.6 million. LeMaitre Vascular also updated its FY 2024 guidance to 1.910-1.960 EPS.

LeMaitre Vascular Trading Down 0.7 %

Shares of NASDAQ LMAT traded down $0.66 during midday trading on Thursday, hitting $88.39. 191,960 shares of the company’s stock were exchanged, compared to its average volume of 122,304. The business’s fifty day moving average price is $89.48 and its two-hundred day moving average price is $82.73. The company has a market cap of $1.99 billion, a price-to-earnings ratio of 52.93, a PEG ratio of 2.29 and a beta of 0.88. LeMaitre Vascular has a 12-month low of $45.96 and a 12-month high of $93.32.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.05. The business had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The business’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.37 EPS. Equities analysts expect that LeMaitre Vascular will post 1.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on LMAT. Cantor Fitzgerald started coverage on LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price on the stock. Lake Street Capital assumed coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price objective on the stock. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. Barrington Research reiterated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. Finally, JMP Securities boosted their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 20th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $94.67.

Insider Activity

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.79% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.